# Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans

> **NCT04596644** · PHASE2 · SUSPENDED · sponsor: **New York State Psychiatric Institute** · enrollment: 16 (estimated)

## Conditions studied

- Cannabis
- Pain
- Tolerance
- Hyperalgesia

## Interventions

- **DRUG:** Active Cannabis
- **DRUG:** Placebo Cannabis

## Key facts

- **NCT ID:** NCT04596644
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-08-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 16 (ESTIMATED)
- **Why stopped:** In response to quality assurance and compliance concerns, OHRP issued an FWA restriction on NYSPI research that included a pause of human research as of June 23, 2023.
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04596644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04596644, "Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04596644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*